A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER

被引:35
作者
Dudderidge, Tim [1 ]
Stockley, Jacqui [2 ]
Nabi, Ghulam [3 ]
Mom, Jaswant [4 ]
Umez-Eronini, Nkemi [5 ]
Hrouda, David [6 ]
Cresswell, Jo [7 ]
McCracken, Stuart Robert Crozier [8 ]
机构
[1] Univ Hosp Southampton NHS Fdn Trust, Dept Urol, Southampton, Hants, England
[2] Arquer Diagnost Ltd R&D, Sunderland, England
[3] Ninewells Hosp, Dept Urol, Dundee, Scotland
[4] West Cumberland Hosp, Dept Urol, Whitehaven, England
[5] Cumberland Infirm, Dept Urol, Carlisle, England
[6] Charing Cross Hosp, Dept Urol, London, England
[7] James Cook Univ Hosp, Dept Urol, Middlesbrough, Cleveland, England
[8] Sunderland Royal Hosp, Dept Urol, Sunderland, England
关键词
Bladder cancer; Diagnosis; Urine test; Enzyme-linked immunosorbent assay; CARCINOMA; DIAGNOSIS;
D O I
10.1016/j.euo.2019.06.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bladder cancer is the sixth most commonly diagnosed cancer in the European Union. Here, we evaluate the performance of a novel, commercially available enzyme-linked immunosorbent assay utilising MCM5 antibodies (ADXBLADDER; Arquer Diagnostics Ltd, Sunderland, UK) for the detection of bladder cancer, in a blinded, prospective study of 856 patients, across seven centres, presenting with haematuria. The results were compared with the patients' clinical data and final diagnosis as defined by the results of the imaging and cystoscopy, with a prevalence of bladder cancer of 8.6%. ADXBLADDER detected bladder tumours in 54/74 cancers, giving overall sensitivity of 73.0% and an overall negative predictive value (NPV) of 96.4%. Sensitivity and NPV of ADXBLADDER were highest in muscle-invasive bladder cancer, both at 100%, and on analysis of non-pTa (pT1 and above) tumours, the sensitivity for detection was 97% with an NPV of 99.8%. A subset of 173 patients had matching cytology data; of these patients, 18 were positive for bladder cancer. ADXBLADDER detected 16/18 of these cancers, whilst cytology was positive in only four of 18, providing evidence that ADXBLADDER may be a more sensitive test for bladder cancer than standard urine cytology. Patient summary: We conducted a large clinical study of a novel, simple urine test (ADXBLADDER), which measures a protein (MCM5) in urine and can be used to detect bladder cancer in patients. We recruited 856 patients and demonstrated that the new urine test can detect bladder cancer with a high degree of accuracy, performing better than the most commonly used urine test-urine cytology. In conclusion, this novel ADXBLADDER urine test can be used to help detect bladder cancers and it can replace the current, standard urine test. (C) 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:42 / 46
页数:5
相关论文
共 8 条
[1]   EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].
Babjuk, Marko ;
Boehle, Andreas ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Hernandez, Virginia ;
Kaasinen, Eero ;
Palou, Joan ;
Roupret, Morgan ;
van Rhijn, Bas W. G. ;
Shariat, Shahrokh F. ;
Soukup, Viktor ;
Sylvester, Richard J. ;
Zigeuner, Richard .
EUROPEAN UROLOGY, 2017, 71 (03) :447-461
[2]   Bladder Cancer Diagnosis and Identification of Clinically Significant Disease by Combined Urinary Detection of Mcm5 and Nuclear Matrix Protein 22 [J].
Kelly, John D. ;
Dudderidge, Tim J. ;
Wollenschlaeger, Alex ;
Okoturo, Odu ;
Burling, Keith ;
Tulloch, Fiona ;
Halsall, Ian ;
Prevost, Teresa ;
Prevost, Andrew Toby ;
Vasconcelos, Joana C. ;
Robson, Wendy ;
Leung, Hing Y. ;
Vasdev, Nikhil ;
Pickard, Robert S. ;
Williams, Gareth H. ;
Stoeber, Kai .
PLOS ONE, 2012, 7 (07)
[3]   Economic Burden of Bladder Cancer Across the European Union [J].
Leal, Jose ;
Luengo-Fernandez, Ramon ;
Sullivan, Richard ;
Witjes, J. Alfred .
EUROPEAN UROLOGY, 2016, 69 (03) :438-447
[4]   How important is urinary cytology in the diagnosis of urological malignancies? [J].
Nabi, G ;
Greene, DR ;
O'Donnell, M .
EUROPEAN UROLOGY, 2003, 43 (06) :632-636
[5]   Initial high-grade T1 urothelial cell carcinoma:: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients [J].
Orsola, A ;
Trias, I ;
Raventós, CX ;
Español, I ;
Cecchini, L ;
Búcar, S ;
Salinas, D ;
Orsola, I .
EUROPEAN UROLOGY, 2005, 48 (02) :231-238
[6]  
Shariat Shahrokh F, 2008, Rev Urol, V10, P120
[7]  
Stoeber K, 2002, J NATL CANCER I, V94, P1071
[8]   Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials [J].
Sylvester, RJ ;
van der Meijden, APM ;
Oosterlinck, W ;
Witjes, JA ;
Bouffioux, C ;
Denis, L ;
Newling, DWW ;
Kurth, K .
EUROPEAN UROLOGY, 2006, 49 (03) :466-477